Pharming Group (PHGUF) Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Pharming Group (OTCMKTS:PHGUF) from a hold rating to a sell rating in a research note released on Wednesday morning.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

Several other research firms have also recently weighed in on PHGUF. ValuEngine cut shares of Pharming Group from a hold rating to a sell rating in a research report on Friday, December 1st. HC Wainwright reiterated a buy rating on shares of Pharming Group in a research report on Thursday, October 26th.

Pharming Group (OTCMKTS:PHGUF) traded up $0.05 during mid-day trading on Wednesday, hitting $1.50. 325 shares of the stock traded hands, compared to its average volume of 77,387. Pharming Group has a 12-month low of $0.27 and a 12-month high of $1.58. The company has a quick ratio of 1.27, a current ratio of 1.77 and a debt-to-equity ratio of 11.72.

ILLEGAL ACTIVITY NOTICE: “Pharming Group (PHGUF) Lowered to Sell at Zacks Investment Research” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply